The German biotechnology firm BioNTech, once a beacon of innovation and a financial titan thanks to its pioneering mRNA COVID-19…
Read More
BioNTech Pivots Dramatically to Oncology Amidst Waning Vaccine Revenue and Federal Shift, Cutting 1,860 Jobs and Investing €16.8 Billion in Cash
The German biotechnology powerhouse BioNTech, once synonymous with its groundbreaking COVID-19 vaccine, Comirnaty, is undergoing a profound strategic transformation, shedding…
Read More
